Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/9/2026

Pregabalin Adverse Effects

Neurological Effects

  • Dizziness occurs in 23-46% of patients, and somnolence occurs in 15-25% of patients, according to the Centers for Disease Control and Prevention guidelines 1, 2
  • Cognitive effects, including confusion, are common, particularly at higher doses, as reported by the Centers for Disease Control and Prevention 1, 2

Peripheral Effects

  • Weight gain is a recognized side effect of pregabalin, as stated by the Centers for Disease Control and Prevention 1, 2
  • Peripheral edema occurs in approximately 10% of patients and is dose-dependent, according to the American College of Physicians 3

Clinical Implications

  • If a patient on pregabalin develops bruising, alternative causes should be investigated, such as concurrent anticoagulant or antiplatelet use, as recommended by the European Society of Cardiology 4
  • Evaluate for NSAIDs, SSRIs, or SNRIs that increase bleeding risk, as suggested by the European Society of Cardiology 4
  • Consider other medications or medical conditions causing thrombocytopenia, as advised by the European Society of Cardiology 4
  • Check complete blood count if bruising is unexplained, as recommended by the European Society of Cardiology 4

Pregabalin‑Associated Weight Gain and Increased Appetite

Adverse Effect Profile

  • Pregabalin consistently leads to weight gain and heightened appetite, but the literature does not describe these changes as “extreme hunger” or pathological hyperphagia【5】.

Pharmacologic Comparison within Antiepileptic Drugs

  • Both pregabalin and gabapentin are reliably linked to weight gain, setting them apart from weight‑neutral antiepileptics such as lamotrigine, levetiracetam, and phenytoin【6】.

Management Recommendations

  • Because weight‑related adverse effects increase with higher doses, clinicians should consider dose reduction or switching to alternative agents when weight gain becomes clinically significant【7】.